www.亚洲免费av,成人综合影院,久久久精品天堂

中文站

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Company News

Company News Exhibitions Activities

All news 2025 2024 2023 2022 2021 2018

Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (GRADUAL-1) of Bofanglutide (GZR18) injection in Chinese Patients with Overweight or Obesity
Gan & Lee 2024-12-30
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
Gan & Lee 2024-11-13
ObesityWeek?? 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
Gan & Lee 2024-11-12
Malaysian Deputy Prime Minister Attends Groundbreaking Ceremony of Gan & Lee Pharmaceuticals' Partner Factory
Gan & Lee 2024-11-11
Gan & Lee Pharmaceuticals Shines at CPHI Worldwide 2024 in Milan
Gan & Lee 2024-10-17
Gan & Lee Pharmaceuticals’ Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies
Gan & Lee 2024-10-16

1 2 3 4 5 >

Our websites

Gangan Technology

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back

Search

Subscribe